- Report
- February 2026
- 250 Pages
Global
From €4223EUR$4,490USD£3,523GBP
- Report
- August 2026
- 116 Pages
Global
From €4467EUR$4,750USD£3,727GBP
- Report
- July 2026
- 150 Pages
Global
From €3527EUR$3,750USD£2,942GBP
- Report
- January 2026
- 53 Pages
Global
From €1129EUR$1,200USD£941GBP
- Report
- November 2026
- 160 Pages
Global
From €3903EUR$4,150USD£3,256GBP
- Report
- October 2026
- 160 Pages
Global
From €3122EUR$3,320USD£2,605GBP
€3903EUR$4,150USD£3,256GBP
- Report
- October 2026
- 308 Pages
Global
From €3500EUR$3,986USD£3,022GBP
- Report
- February 2026
- 133 Pages
Global
From €3500EUR$3,986USD£3,022GBP
- Report
- June 2026
- 150 Pages
Global
From €4561EUR$4,850USD£3,805GBP
- Report
- December 2025
- 100 Pages +
Global
€4990EUR$5,684USD£4,308GBP
- Report
- May 2026
- 95 Pages
North America
From €3057EUR$3,250USD£2,550GBP
- Report
- March 2026
- 281 Pages
United States
From €4561EUR$4,850USD£3,805GBP
- Report
- May 2026
- 700 Pages
Global
From €4698EUR$4,995USD£3,919GBP
- Report
- November 2026
- 262 Pages
Global
From €6579EUR$6,995USD£5,488GBP
- Report
- October 2026
- 161 Pages
Global
From €6579EUR$6,995USD£5,488GBP
- Report
- October 2026
- 209 Pages
Global
From €4513EUR$4,799USD£3,765GBP
- Report
- October 2026
- 641 Pages
Global
From €4513EUR$4,799USD£3,765GBP
- Report
- September 2026
Global
From €4513EUR$4,799USD£3,765GBP
- Report
- July 2026
- 575 Pages
Global
From €4513EUR$4,799USD£3,765GBP
- Report
- June 2026
- 77 Pages
Global
From €4513EUR$4,799USD£3,765GBP

The Antibody Drug Conjugate (ADC) market is a subset of the biotechnology industry that focuses on the development of targeted therapies for cancer and other diseases. ADCs are composed of an antibody, a linker, and a cytotoxic drug. The antibody binds to a specific target on the surface of a cell, and the linker and drug are released when the ADC binds to the target. This allows for the delivery of a high dose of the drug to the target cell, while minimizing the damage to healthy cells.
ADCs have been used to treat a variety of cancers, including breast, ovarian, and non-small cell lung cancer. They have also been used to treat other diseases, such as autoimmune disorders and infectious diseases.
The ADC market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Seattle Genetics, ImmunoGen, Pfizer, Merck, and Novartis. Show Less Read more